Senator Bernie Sanders is seeking a meeting with Novo Nordisk A/S’s top executive to address the high cost of the blockbuster drug Ozempic, particularly in relation to GLP-1 drugs for diabetes and obesity. The Vermont independent is contemplating holding hearings on the pricing of these drugs and hopes to have a personal conversation with Novo's CEO, Lars Fruergaard Jørgensen, before making any decisions. This move has ignited controversy over the pricing of crucial medications for chronic conditions and signals potential action to combat rising drug costs in the healthcare market.